TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study of 29 healthy adults found that a treatment combining temporary blood-pressure reduction with whole-body vibration was associated with increased levels of several brain-derived proteins in blood. The researchers say the findings suggest enhanced brain protein clearance, but the study did not test whether the approach prevents or treats dementia.
Researchers in Finland report that a treatment combining temporary blood-pressure reduction and whole-body vibration was associated with increased levels of dementia-linked proteins in the blood of 29 healthy adults, a finding they say suggests the brain cleared more of these proteins. The study, published in Nature Communications on November 3, examined a possible way to enhance the brain’s natural waste-clearance processes; it did not test whether the treatment prevents dementia or benefits patients.
The study was conducted by researchers at the University of Oulu and Oulu University Hospital. The team combined medication that temporarily lowers blood pressure with rhythmic whole-body vibration intended to stimulate blood-vessel responses. Researchers assessed the participants using multimodal MRI, physiological measurements and blood-based biomarkers thought to originate in the brain.
After treatment, blood levels of several soluble brain-derived proteins increased, including beta-amyloid 40 and 42 and GFAP. MRI and measurements of cerebrospinal-fluid circulation also showed changes in fluid flow and protein concentrations. The authors interpret these findings as evidence of increased protein movement out of the brain. A rise in blood levels is an indirect measure, however; it does not by itself establish how much protein was removed or whether deposits in brain tissue were reduced.
The researchers linked the two parts of the intervention to different mechanisms. The medication’s temporary blood-vessel dilation strengthened slow brain pulsations associated with fluid movement, while vibration was designed to activate mechanosensitive Piezo1 channels in blood vessels. The treatment was assessed in healthy adults, not in people diagnosed with dementia or early memory impairment.
A Possible Route to Brain Waste Clearance
Alzheimer’s disease and other dementias are associated with the gradual accumulation of proteins in the brain. The study raises the possibility that the brain’s own clearance pathways could be influenced while a person is awake, rather than relying only on processes that are especially active during sleep. That is a research lead, not evidence that the intervention can prevent disease.
The distinction matters because the experiment measured short-term changes in healthy volunteers, not long-term cognitive outcomes. It did not establish whether the protein changes reduce harmful deposits, improve memory, or affect the risk or course of dementia. Any future value will depend on whether further studies reproduce the findings and show safe, meaningful benefits in relevant patient groups.
Products Worth Considering
Levoit Vital 100S-P Air Purifier for Home and Pets
LEVOIT Air Purifier for Home, Pets, Bedroom, Smart WiFi
Fitbit Inspire 3 Health and Fitness Tracker Bundle
As an affiliate, we earn on qualifying purchases.
How the Treatment Targets Fluid Flow
The brain’s clearance mechanisms move cerebrospinal fluid and waste products through and around brain tissue. These processes are known to vary with sleep. The study’s rationale drew partly on earlier mouse research in which temporarily lowering blood pressure was linked to increased clearance of cerebrospinal fluid and molecules it carries.
Researchers also cited animal studies connecting Piezo1 activation with changes in meningeal lymphatic flow and lower beta-amyloid burden. Those findings informed the use of vibration in the human study, but results in animals do not establish that the same effects occur in people. The current report, “Vasomechanic treatment is associated with increased efflux of human brain proteins,” describes an association in a small human study, rather than proof of a dementia treatment.
“The next step is to investigate what benefits the treatment might offer patients with early-stage memory impairment.”
— Vesa Kiviniemi
Clinical Effects Remain Untested
The study involved 29 healthy volunteers and does not show whether the approach is safe or effective over repeated or longer-term use, or for people with memory impairment or dementia. The source report does not specify enough detail to assess the size and duration of the protein changes, how long any effect lasted, or whether participants experienced adverse effects.
It is also unclear whether increased protein levels in blood translate into a lasting reduction of proteins in brain tissue. The researchers describe the results as suggesting greater clearance, but the study did not report that participants had fewer brain deposits, improved cognition, or a lower future dementia risk. Those outcomes remain unconfirmed.
Studies in Memory-Impaired Patients
Kiviniemi said the team is planning follow-up studies with other researchers to investigate possible benefits for people with early-stage memory impairment. The source report does not provide a timetable, trial size or protocol for that work.
Further research would need to test whether the findings can be reproduced, establish the treatment’s safety and determine whether changes in brain-derived proteins lead to meaningful clinical outcomes. Until then, the work is an early human research finding, not an available dementia prevention or treatment method.
Key Questions
What did the treatment involve?
It combined medication that temporarily lowers blood pressure with rhythmic whole-body vibration intended to affect blood-vessel function.
What did researchers observe?
Blood levels of beta-amyloid 40 and 42, GFAP and other brain-derived proteins increased after treatment. The researchers say this, alongside MRI and fluid-flow findings, suggests increased movement of proteins out of the brain.
Does this show the treatment can prevent Alzheimer’s disease?
No. The study involved healthy adults and did not measure dementia prevention, cognitive improvement or changes in brain protein deposits over time.
What happens next?
The researchers say they are planning follow-up studies, including research into potential effects in people with early-stage memory impairment. A timeline and study details have not been reported.
Source: news-medical.net
